Skip to main content
Fig. 2 | BMC Women's Health

Fig. 2

From: Contemporary treatment utilization among women diagnosed with symptomatic uterine fibroids in the United States

Fig. 2

Treatments and time to treatment for the Commercial cohort; 12-month follow-up. aIncludes IUD/levonorgestrel implants, oral contraceptives, and other contraceptives; hormonal contraceptives were not mutually exclusive and a patient could receive > 1 type. bDoes not include women with hysterectomy as first-line procedure. GnRH: gonadotropin-releasing hormone; IUD: intrauterine device; NSAID: non-steroidal anti-inflammatory drug; SD: standard deviation; SERM: selective estrogen receptor modulator

Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us